Dashboard
1
Poor Management Efficiency with a low ROCE of 7.16%
- The company has been able to generate a Return on Capital Employed (avg) of 7.16% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 6.29% and Operating profit at -5.85% over the last 5 years
4
Flat results in Jun 26
5
With ROE of 4.50%, it has a very attractive valuation with a 1.62 Price to Book Value
6
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,717 Million (Small Cap)
36.00
NA
0.80%
0.11
4.50%
1.51
Revenue and Profits:
Net Sales:
365 Million
(Quarterly Results - Jun 2026)
Net Profit:
28 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.02%
0%
8.02%
6 Months
-10.45%
0%
-10.45%
1 Year
-4.97%
0%
-4.97%
2 Years
27.66%
0%
27.66%
3 Years
-4.76%
0%
-4.76%
4 Years
-4.28%
0%
-4.28%
5 Years
-27.55%
0%
-27.55%
Qingdao Vland Biotech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.29%
EBIT Growth (5y)
-5.85%
EBIT to Interest (avg)
12.66
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.14
Sales to Capital Employed (avg)
0.53
Tax Ratio
18.92%
Dividend Payout Ratio
36.25%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.31%
ROE (avg)
7.19%
Valuation key factors
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
1.62
EV to EBIT
34.61
EV to EBITDA
17.25
EV to Capital Employed
1.55
EV to Sales
2.23
PEG Ratio
NA
Dividend Yield
0.74%
ROCE (Latest)
4.49%
ROE (Latest)
4.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
364.60
338.60
7.68%
Operating Profit (PBDIT) excl Other Income
56.20
52.00
8.08%
Interest
2.40
7.40
-67.57%
Exceptional Items
6.10
4.20
45.24%
Consolidate Net Profit
27.90
23.20
20.26%
Operating Profit Margin (Excl OI)
78.40%
71.70%
0.67%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 7.68% vs 6.18% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 20.26% vs -7.57% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,360.60
1,307.50
4.06%
Operating Profit (PBDIT) excl Other Income
205.40
225.60
-8.95%
Interest
18.80
22.80
-17.54%
Exceptional Items
29.70
6.60
350.00%
Consolidate Net Profit
97.50
92.20
5.75%
Operating Profit Margin (Excl OI)
64.00%
86.70%
-2.27%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4.06% vs 9.39% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 5.75% vs -10.40% in Dec 2024
About Qingdao Vland Biotech Co., Ltd. 
Qingdao Vland Biotech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






